Taiwan and Puerto Rico have never been obvious trading partners. What has changed is the context in which manufacturing decisions are now made.
Companies are no longer optimizing only for cost. They are optimizing for regulatory certainty, supply chain resilience, and proximity to the markets that ultimately buy the product. For Taiwanese manufacturers evaluating where to place their next facility, those three priorities increasingly point to the same jurisdiction.
Puerto Rico is not a new destination for Asian investment. It is an established one that Taiwan has only recently begun to use.
Two Islands, Comparable Weight
Taiwan was the world’s twelfth-largest exporter in 2025, its strongest ranking in more than three decades, and it produces roughly 92% of the world’s most advanced semiconductors. Puerto Rico carries comparable weight in a different discipline. The island exported $48.3 billion in pharmaceuticals and another $6 billion in medical devices in fiscal 2024, the bulk of its $65.4 billion in total exports. Two islands, each carrying a global footprint far larger than its geography suggests, each built on precision, regulatory discipline, and decades of accumulated technical capability.
The parallels extend past economics. Puerto Rico anchors the U.S. presence in the Caribbean. Taiwan anchors it in the Indo-Pacific. Both are critical nodes in U.S. trade and security strategy, and both have built distinct cultural identities that drive economic ambition.
That familiarity matters more than it appears. For companies headquartered in Asia, operating in a U.S. jurisdiction is not only a compliance question. It is a question of how teams communicate, how decisions get made, and how quickly trust is established. Puerto Rico combines the structure of the U.S. business environment with a bilingual, relationship-driven workforce, and that combination reduces friction from the first day of operations.
Competing as a U.S. Jurisdiction
Puerto Rico does not compete as a Caribbean location. It competes as a U.S. one.
The U.S. dollar is the official currency. U.S. federal law applies, including intellectual property and patent protections. U.S. banking regulation applies, including FDIC coverage. FDA and ISO frameworks govern regulated production. Goods manufactured on the island carry the “Made in USA” designation.
For a Taiwanese manufacturer, the practical consequence is that serving the U.S. market stops requiring a border crossing. Trade between Puerto Rico and Taiwan operates under U.S. trade law, and the U.S.-Taiwan Agreement on Reciprocal Trade signed in February 2026 addresses tariff treatment, market access in sectors including pharmaceuticals and medical devices, safety standards alignment, and export control alignment. Relief from double taxation is the one piece still in motion: legislation to provide it passed the U.S. House in January 2025 and awaits action in the Senate.
Complementary, Not Competing
Taiwan leads in semiconductor fabrication, electronics production, and industrial automation. Puerto Rico’s strength sits in FDA-regulated bioscience, precision manufacturing, and the electronics base that supports both. These are adjacent capabilities, not overlapping ones.
The island’s computer and electronics manufacturing sector represents $10.6 billion in output, roughly 20% of total manufacturing GDP, with companies including Jabil, Eaton, and Collins Aerospace already operating there. Employment in computer and electronics manufacturing grew 29% between 2020 and 2024.
For Taiwanese biotech and medical device firms, the alignment is more direct. Puerto Rico offers more than 70 years of experience in pharmaceutical and medical device manufacturing. AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, and Eli Lilly manufacture on the island, and so do Boston Scientific, Medtronic, Stryker, and Zimmer Biomet.
Four factors consistently shape the decision:
- A fixed and predictable tax position: a 4% fixed corporate income tax rate for qualifying activities under an Act 60 decree, compared with a 21% federal rate on the U.S. mainland that reaches 32.5%once state taxes are added in the highest-tax states.
- Technical talent at scale: more than 80 accredited universities and colleges, more than 16,000 STEM degrees awarded each year, and a first-place national ranking for graduating underrepresented minorities in engineering.
- Incentives structured around capital deployment: a 50% R&D tax credit that can be transferred or sold; a 25% credit on purchases of products manufactured in Puerto Rico; cash grants tied to job creation, machinery, and infrastructure; and matching funds for workforce training.
- Logistics built for regulated goods: three international airports, the highest-volume seaport system in the Caribbean, trade reach to more than 85 countries, established cold chain capability, and the largest non-contiguous Foreign Trade Zone system in the United States.
Honeywell illustrates the research-intensive end of that profile. The company built a $35 million electromagnetic and environmental testing laboratory in Moca and has grown an aerospace engineering operation around it in the island’s western region.
What the First Taiwanese Investment Signals
The strongest evidence for this case is that a Taiwanese company has already acted on it.
PharmaEssentia, headquartered in Taipei, formalized a $46 million investment in March 2026 to establish a biopharmaceutical manufacturing subsidiary in Toa Baja, supporting U.S. production and long-term global demand for BESREMi®, an FDA-approved biologic therapy for polycythemia vera, a rare blood cancer. More than 90 specialized jobs are planned in the initial phase, with operations targeted to commence in 2027.
As the first Taiwanese biopharmaceutical company to manufacture in Puerto Rico, the decision carries weight beyond its capital figure. It reflects confidence in the island’s regulatory environment, workforce capability, and long-term competitiveness, and it establishes a reference point that other Taiwanese companies can evaluate.
That decision also sits within broader momentum. Eli Lilly committed more than $1.2 billion to modernize and expand operations in Carolina. Amgen announced a $650 million expansion in Juncos. Terumo inaugurated a $45 million medical device plant in Caguas. Labor force participation reached 44.8% in 2025, its highest level in 16 years, and unemployment, at 6.0% in July 2026, sits near the lowest levels in the island’s recorded history.
Looking Ahead: Building the Taiwan Corridor
Taiwanese investment in Puerto Rico is at an early stage, and that is precisely where the opportunity sits. The regulatory alignment exists. The industrial complementarity is clear. The first anchor investment is underway.
What remains is sustained engagement between the two islands, sector by sector and company by company. Attracting investment from Asia is measured in years rather than quarters, and it requires presence, consistency, and follow-through.
Invest Puerto Rico will continue to prioritize Taiwan and the wider Asia region as a strategic market, supporting companies through market intelligence, site selection, government navigation, talent integration, and long-term operational growth. For manufacturers whose next facility must serve the U.S. market from inside it, Puerto Rico remains well positioned to compete.
